For five decades, Stuart Orkin has harnessed new genetic tools to transform care for blood disorders – helping make sickle cell and beta thalassemia curable.
Navepegritide is described as the first therapy to deliver continuous C-type natriuretic peptide exposure over a weekly dosing interval in eligible pediatric patients.
As more states expand adult Medicaid dental benefits, participation remains low and GOP-backed federal cuts threaten to reverse recent progress, raising concerns for physicians and dentists.